[Role of ceftaroline fosamil in the treatment of bacteremia and infectious endocarditis].
Ceftaroline fosamil is a new subclass of cephalosporins with high intrinsic activity against various multi-resistant Gram-positive organisms, including Staphylococcus aureus and Streptococcus pneumoniae, as well as against Enterobacteriaceae causing bacteremia and infective endocarditis. Because of its pharmacokinetic profile and pharmacodynamic characteristics, this drug is a good therapeutic option for these infections. Experimental studies have shown good clinical efficacy for the treatment of endocarditis caused by S. aureus, regardless of their sensitivity to methicillin or vancomycin. Clinical experience is limited, although clinical trials and case series have reported a favorable clinical response in patients with bacteremia associated with skin and soft tissue infections, pneumonia, or infective endocarditis. Future studies should define more precisely the role of this new antibiotic in the treatment of these infections.
Servicio de Enfermedades Infecciosas, Hospital Universitari Vall d'Hebron, Barcelona, España. Electronic address: balmirante@vhebron.net.
Benito
B
Almirante
Servicio de Enfermedades Infecciosas, Hospital Clínic, Universidad de Barcelona, Barcelona, España.
Juan M
JM
Pericás
Servicio de Enfermedades Infecciosas, Hospital Clínic, Universidad de Barcelona, Barcelona, España.
José M
JM
Miró
D000818:Animals; D016470:Bacteremia / Q000188:drug therapy*; D002511:Cephalosporins / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004195:Disease Models, Animal; D004697:Endocarditis, Bacterial / Q000188:drug therapy*; D006801:Humans; D013203:Staphylococcal Infections / Q000188:drug therapy; D000097583:Ceftaroline
D002511:Cephalosporins; D000097583:Ceftaroline
Bacteremia; Bacteriemia; Ceftarolina; Ceftaroline; Endocarditis infecciosa; Infective endocarditis; Staphylococcus aureus